Novel cancer drug stymied by rigid billing system
The problem is that there is no billing code for the US$373,000 Yescarta therapy in Medicare
Minneapolis
A US government reimbursement system that does not fully cover the costs for Gilead Sciences Inc's complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, according to doctors who are trying to treat patients.
Only a handful of patients have received the therapy, Yescarta, two months after its approval, while waiting lists have risen to the hundreds at the 15 cancer centres authorised to administer the treatment in the US, Bloomberg News reported last Thursday.
TRENDING NOW
Singapore identifies 7 firms responsible for haze fires, notices issued urging action: Grace Fu
Philippine power giant First Gen rebuffs foreign offers, plans up to US$2.6 billion in expansion
DBS remains analysts’ pick ahead of Q3 earnings after Singapore banks’ share slump
Indonesia imposes US$116 million in fines over manipulation of Sinar Mas, Prajogo-linked stocks
